

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

SANOFI-AVENTIS U.S. LLC, SANOFI-
AVENTIS DEUTSCHLAND GMBH, and
SANOFI WINTHROP INDUSTRIE,

Plaintiffs,

v.

MYLAN GMBH, BIOCON LTD., BIOCON
RESEARCH LTD., BIOCON SDN. BHD.,
and BIOCON S.A.

Defendants.

C. A. No. 2:17-09105 (SRC-CLW)

**PLAINTIFFS' PRELIMINARY CLAIM CONSTRUCTIONS AND PRELIMINARY
IDENTIFICATION OF SUPPORTING INTRINSIC AND EXTRINSIC EVIDENCE**

Pursuant to Local Patent Rule 4.2 and the Court's Order (D.I. 23 and D.I. 78), and as agreed by the parties¹, Plaintiffs Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie, (collectively, "Plaintiffs" or "Sanofi") hereby provide to Defendant Mylan GmbH ("Mylan") and Defendants Biocon Ltd., Biocon Research Ltd., Biocon Sdn. Bhd., and Biocon S.A. (collectively, "Biocon") (collectively, "Defendants") in the attached Exhibits A-C Plaintiffs' preliminary claim constructions and preliminary identification of supporting intrinsic and extrinsic evidence.

These disclosures are based upon information reasonably available to Plaintiffs at this time and are made without prejudice to Plaintiffs' right to amend and/or supplement these disclosures in the future as necessary and appropriate, including as a result of the discovery or investigation of further information, including Defendants' supplementation of its non-

¹ September 5, 2018 e-mail from E. Steiner to R. Vlasits.

infringement contentions and/or invalidity contentions. Plaintiffs may also rely on expert testimony regarding the person of ordinary skill in the art (“POSITA”) at the time of the invention to explain the ordinary meaning of any term as it would have been understood by a POSITA or to describe or elucidate any of these terms, including by presenting a technical tutorial to the Court. Finally, Plaintiffs reserve the right to offer further intrinsic evidence and expert testimony and other extrinsic evidence to rebut Defendants’ proposed constructions, intrinsic evidence, expert testimony, or other extrinsic evidence, if any, offered by Defendants in support of their claim constructions.

Dated: September 5, 2018

s/ Liza M. Walsh
Liza M. Walsh
Christine I. Gannon
Katelyn O’Reilly
Walsh Pizzi O’Reilly Falanga LLP
One Riverfront Plaza
1037 Raymond Blvd, Suite 600
Newark, NJ 07102
(973) 757-1101
lwalsh@walsh.law
cgannon@walsh.law
koreilly@walsh.law
Attorneys for Plaintiffs Sanofi-Aventis U.S. LLC,
Sanofi-Aventis Deutschland GmbH, and Sanofi
Winthrop Industrie

Of Counsel:
WEIL, GOTSHAL & MANGES LLP

Elizabeth S. Weiswasser
Anish Desai
Aaron Pereira
Anna Dwyer
Andrew Gesior
Kathryn Kantha
767 Fifth Avenue
New York, New York 10153
(212) 310-8000

elizabeth.weiswasser@weil.com
anish.desai@weil.com
aaron.pereira@weil.com
anna.dwyer@weil.com
andrew.gesior@weil.com
kathryn.kantha@weil.com

Robert T. Vlasits III
Sutton Ansley
Christopher Pepe
Matthew Sieger
2001 M Street NW, Suite 600
Washington, DC 20036
(202) 682-7000
robert.vlasits@weil.com
sutton.ansley@weil.com
christopher.pepe@weil.com
matthew.sieger@weil.com

CERTIFICATE OF SERVICE

I hereby certify that on September 5, 2018, I caused a copy of PLAINTIFFS' PRELIMINARY CLAIM CONSTRUCTIONS AND PRELIMINARY IDENTIFICATION OF SUPPORTING INTRINSIC AND EXTRINSIC EVIDENCE to be served via email on counsel for Defendant.

Dated: September 5, 2018

By: s/Anna E. Dwyer
Anna E. Dwyer
WEIL, GOTSHAL & MANGES LLP
767 Fifth Avenue
New York, New York 10153
(212) 310-8000
anna.dwyer@weil.com

Exhibit A

Plaintiffs' Proposed Preliminary Claim Construction s and Supporting Evidence – U.S. Patent N

TERM	CLAIM(S)	CONSTRUCTION	INTRINSIC EVIDENCE
“at least one chemical entity chosen from”	'652 patent, claim 1, 7, 24	Plain and ordinary meaning, which a POSITA would understand to be “at least one chemical compound chosen from.” No construction necessary.	'652 Patent: Abstract, 1:11-15, 2:23-27; 2:38-41; 3:41-45; 3:50-56; 4:7-27, claims 1, 2, 7, 8, 17-19, 23, 24. U.S. App. No. 11/089,777 File History: March 25, 2005 Transmittal of New Application claims and specification at 1, 3, 5-7; March 21, 2007 claims and Remarks at 6-10; April 25, 2007 Final Office Action at 2-3; July 25, 2007 claims and Remarks at 7-8; August 8, 2007 Non-Final Office Action at 2-3; November 8, 2007 Remarks at 2-7; March 19, 2008 claims and Remarks

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.